Xvivo Perfusion AB (publ) (FRA:3XV)
Germany flag Germany · Delayed Price · Currency is EUR
21.92
+0.96 (4.58%)
At close: Jan 27, 2026

Xvivo Perfusion AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
812.17822.42597.54415.29258.39
Revenue Growth (YoY)
-1.25%37.63%43.89%60.72%43.66%
Cost of Revenue
212.67206152.43118.3470.11
Gross Profit
599.49616.42445.11296.96188.28
Selling, General & Admin
377.09379.77309.21223.38153.38
Research & Development
131.99148.33135.9469.3454.04
Other Operating Expenses
2.04-1.09-5.43-0.22-0.39
Operating Expenses
511.12527.01439.72292.5207.02
Operating Income
88.3889.415.44.45-18.74
Interest Expense
-49.82-1.26-1.19-0.61-0.28
Interest & Investment Income
-17.168.852.12-
Currency Exchange Gain (Loss)
-32.399.6917.095.98
Other Non Operating Income (Expenses)
-63.0472.78-0.4919.75
EBT Excluding Unusual Items
38.56200.7395.5222.586.71
Gain (Loss) on Sale of Assets
--0.78-1-0.26-0.04
Pretax Income
38.56199.9594.5222.316.67
Income Tax Expense
13.427.772.73.89-1.49
Net Income
25.16172.1891.8218.438.15
Net Income to Common
25.16172.1891.8218.438.15
Net Income Growth
-85.39%87.52%398.29%126.04%-
Shares Outstanding (Basic)
3131303029
Shares Outstanding (Diluted)
3232303029
Shares Change (YoY)
-0.29%5.73%1.39%2.04%6.49%
EPS (Basic)
0.805.473.070.620.28
EPS (Diluted)
0.805.443.070.620.28
EPS Growth
-85.31%77.35%394.72%121.43%-
Free Cash Flow
101.0740.563.279.67-22.25
Free Cash Flow Per Share
3.201.280.110.33-0.77
Gross Margin
73.81%74.95%74.49%71.50%72.87%
Operating Margin
10.88%10.87%0.90%1.07%-7.25%
Profit Margin
3.10%20.94%15.37%4.44%3.16%
Free Cash Flow Margin
12.44%4.93%0.55%2.33%-8.61%
EBITDA
138.49110.919.0313.3-11.7
EBITDA Margin
17.05%13.48%3.19%3.20%-4.53%
D&A For EBITDA
50.1121.513.648.857.04
EBIT
88.3889.415.44.45-18.74
EBIT Margin
10.88%10.87%0.90%1.07%-7.25%
Effective Tax Rate
34.74%13.89%2.86%17.42%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.